Pyloric EndoFlip and Its Clinical Use in Gastroparesis

Albis Cecilia Hani de Ardila,[1] 🆔 Aldair Chaar,[2*] 🆔 Juan Hernández,[3] 🆔 Raúl Cañadas,[1] 🆔 María del Carmen Figueredo.[4] 🆔

Abstract

Gastroparesis is a chronic disorder of gastric motility that results in marked impairment of quality of life and significant costs to health care systems. Medical therapies are limited in their management, thus, the reason for a growing enthusiasm for pylorus-targeted therapies. The functional luminal imaging probe (FLIP) is a useful diagnostic tool for assessing pylorus characteristics, especially in refractory cases, which could lead to a better management strategy and, in many cases, predict clinical response.

Keywords

Gastroparesis, pylorus, gastric emptying, electrical impedance, EndoFLIP.

INTRODUCTION

Gastroparesis is a chronic motility disorder characterized by poor gastric accommodation, leading to symptoms such as nausea, vomiting, early satiety, abdominal pain, and weight loss. As a *sine qua non* condition, it is essential to rule out mechanical obstruction and confirm delayed gastric emptying[1]. The annual cost associated with gastroparesis is approximately $568 million dollars[2]. In the United States, the prevalence is 21.5 cases per 100,000 inhabitants, with a higher incidence in females (female-male ratio 3.8:1) and in Caucasians (71.7%), followed by African Americans (15.2%), Hispanics (11.2%), and Asians (1.9%).

Diabetes *mellitus* is the primary cause (57.4%), followed by gastrointestinal surgical procedures, particularly those involving vagotomy (15.0%), medications (11.8%), idiopathic causes (11.3%), and miscellaneous causes (4.5%), which include connective tissue diseases[3]. The pathophysiology involves altered gastric motility or increased pyloric pressure. Disruptions in the accommodation of the gastric body and fundus, antral hypomotility, lack of pyloric relaxation, and small intestine dysmotility can result in delayed gastric emptying. Immune-mediated mechanisms likely play a critical role in the pathogenesis. Structural studies have reported lesions in the interstitial cells of Cajal (ICCs), nerves, and gastric smooth muscle

cells, as well as the loss of macrophages with an anti-inflammatory phenotype[4].

Diagnosis is made through solid-phase gastric emptying scintigraphy, which evaluates gastric emptying by ingesting food labeled with a radiotracer (technetium-99m [^{99m}Tc]). Interpretation is based on measuring the percentage and time of emptying (usually over 4 hours) and the percentage of retention of the labeled food. In patients with > 60% retention at 2 hours or > 10% at 4 hours, the study is considered conclusive for gastroparesis[5].

Complementary methods include the breath test, where a substrate (octanoic acid or *Spirulina platensis*) labeled with a stable carbon isotope (^{13}C) is added to a solid food portion. After digestion and absorption in the small intestine, these substrates are metabolized by the liver, exhaled as ^{13}C through the lungs, and quantified by mass spectrometry[4].

FDA-approved wireless motility capsules are sensitive for detecting delays in gastric emptying, though their clinical relevance is still debated. They also allow for the evaluation of abnormal intestinal transit and are valuable for addressing comorbidities such as constipation associated with gastroparesis[4]. Other techniques like magnetic resonance imaging and ultrasound are useful in research; however, their clinical use faces limitations due to factors like cost and equipment availability[6].

Recently, the functional lumen imaging probe (EndoFLIP) has been validated as an attractive tool for measuring parameters in the pylorus, such as pyloric hypertonia, which is one of the potential pathophysiological mechanisms implicated in delayed gastric emptying. Its potential role in this field is being increasingly studied, given its usefulness in identifying the subtype of patients with pyloric dysfunction who could benefit from pylorus-directed therapies (**Figure 1**).

The treatment of gastroparesis involves a combination of pharmacological and non-pharmacological strategies. A fractionated diet (4 to 5 low-fat and low-fiber portions daily) is fundamental[7], followed by the use of prokinetics such as metoclopramide, domperidone, and levosulpiride.

Despite these measures, up to 40% of patients develop refractory gastroparesis[8], which the American Gastroenterological Association (AGA) defines as persistent symptoms despite dietary adjustments and at least four weeks of effective therapy with first-line prokinetics at an optimal dose and with adequate adherence[9].

Alternative therapies have been employed, such as hydraulic balloon pyloric dilation (HBPD), botulinum toxin (BT), laparoscopic pyloromyotomy, and gastric pacemakers, with varying success rates (43% to 77%[10], 83% to 86%[11], and 53.7%, respectively[12]).

Gastric peroral endoscopic myotomy (G-POEM) has emerged as an innovative option with technical and clinical success and a positive impact on quality of life[13]. Despite an adverse event rate of 5%-10%[14], G-POEM shows efficacy similar to laparoscopic pyloroplasty but with shorter procedure times and fewer complications, making it a potentially preferred choice for refractory gastroparesis, especially in those documented with pyloric hypertonia[15].

THE PYLORIC SPHINCTER: A ZONE OF SPECIAL INTEREST IN GASTRIC EMPTYING

The pyloric sphincter is a narrow area of smooth muscle with increased luminal pressure located between the stomach and the duodenum. Its function is regulated by intrinsic innervation from the gastric myenteric plexus and extrinsic innervation through branches of the vagus nerve. Hence, pyloric dysfunction represents a key mechanism in gastroparesis, whose nature can vary depending on the underlying cause[4]. The contractions and relaxations of the pylorus depend on the transmission of nerve signals through the ICCs and the response of smooth muscle cells. There are at least two independently controlled functional areas: the circular muscle near the myenteric plexus, dominated by the propagation of gastric slow waves, resulting in sphincter contractions at the end of each peristaltic movement, and the deeper circular muscle, regulated by motor neurons, where slow waves have no influence. The pylorus has garnered increasing interest because its relaxation in synchrony with motor activity between the antrum and the duodenum facilitates gastric emptying[8].

ENDOFLIP DEVICE AND ITS OPERATIONAL CHARACTERISTICS

EndoFLIP is a widely used diagnostic tool in the esophagus for evaluating the lower esophageal sphincter (LES). It utilizes a catheter with 16 sensors that, when inflated, measures diameter (D), pressure (P), cross-sectional area (CSA), and distensibility index (DI). The DI indicates the sphincter's ability to stretch and is calculated by measuring the CSA at the narrowest point of the sphincter and dividing it by its P. There are two catheter models: EF-325 and EF-322, which differ in length (8 cm and 16 cm respectively) and the distance between their sensors (1 cm and 2 cm respectively). LES measurements have been standardized and are represented through the FLIP 1.0 and FLIP 2.0 modules as a 3D topographic image of the esophagus[16].

Its use at the pyloric level shares similar procedural characteristics. After a minimum fast of six hours for non-clear liquids and two hours for water, the patient should be positioned in the left lateral decubitus position and sedated. A therapeutic endoscope is inserted through the esophagus into the stomach and antrum, where an endoscopic

Figure 1. Pyloric EndoFLIP with decreased diameter and pyloric distensibility index in a patient with gastroparesis. Images show (**A**) balloon inflated to 40 mL and (**B**) to 50 mL. Author's file.

examination is performed before crossing the pylorus. Next, the EndoFLIP catheter (ideally the pyloric model EF-325N) is zero-calibrated and lubricated with conductive gel before being inserted through the working channel of the endoscope. Once the catheter is positioned in the pylorus under direct visualization, the balloon is inflated at a rate of 1 mL/s until reaching 40 mL-50 mL (optimal observation of the pyloric contour is obtained at 40 mL). Pressure is then measured for five seconds in mmHg using the pressure transducer located in the probe. For

CSA measurement, conductive liquid is perfused through the infusion port at the proximal end of the probe, obtaining an impedance value by planimetry based on Ohm's law (voltage = current x resistance); the diameter is then derived as the square root of 4 CSA/π. The DI (a measure indicating the ease of structure stretching) is derived from the ratio between the CSA and P at the narrowest point of the sphincter. Elasticity, providing information on the ease of stretching along the entire sphincter, is calculated similarly to the DI but considers the total volume from 1 cm above to 1 cm below the narrowest point of the sphincter. After completing the pyloric measurement, the catheter is withdrawn through the channel, and the upper endoscopic examination is completed with direct visualization of the pylorus and duodenum to rule out lesions caused by previous treatments and the examination itself[17-19]. It should be noted that general anesthesia may cause a slight increase in P and a decrease in pyloric DI, which should be corroborated with prospective trials[20].

PYLORUS MEASUREMENTS

For the accurate interpretation of measurements in the pylorus, it is crucial to consider two aspects. The first aspect is the position of the FLIP catheter balloon in relation to the pylorus. Three positions have been predefined: proximal (with 75% of the balloon in the duodenum and 25% in the antrum), mid (50% in the duodenum and 50% in the antrum), and distal (25% in the duodenum and 75% in the antrum). Yim and colleagues demonstrated that the balloon's position relative to the pylorus results in different measurements of DI, CSA, and P (**Table 1**). Specifically, the measurement of P was significantly higher when most of the balloon was distal to the pylorus and folded in the second part of the duodenum compared to when most of the balloon was in the antrum. The pyloric DI is significantly lower when the balloon is primarily positioned in the duodenum compared to the stomach. These findings may be due to balloon deformation and changes in geometry or spatial arrangement when placed within the duodenum.

The second aspect concerns the geometry of the duodenal bulb. The FLIP catheter runs straight at the level of the LES. However, in the case of the pylorus, where esophageal EndoFLIP catheters are commonly used, the curved geometry of the duodenal bulb causes balloon deformation. Consequently, the sensors do not remain centered, affecting the CSA estimates of the pyloric sphincter through impedance planimetry. Since DI measurements are calculated from CSA, it is not surprising to see alterations in this parameter with different positions[19]. Therefore, it is concluded that positioning the FLIP catheter balloon prima-

rily in the antrum (distal) minimizes deformation, allowing for more reliable measurements.

Table 1. Variation of EndoFLIP Measurements Related to the Balloon Position with Respect to the Pylorus

Measurement	Inflation Volume (mL)	Proximal Position	Mid Position	Distal Position
CSA (mm²)	40	130.1	137.9	115.0
	50	183.0	190.2	185.8
Average pressure (mmHg)	40	15.2	11.6	10.6
	50	28.1	31.5	21.1
Distensibility index (mm²/mm Hg)	40	9.8	13.9	13.1
	50	6.7	9.4	9.6

Adapted from: Yim B and colleagues; J Neurogastroenterol Motil. 2023;29(2):192-99.

Several studies have addressed defining reference values for pyloric EndoFLIP measurements. Gourcerol and colleagues evaluated a cohort of healthy volunteers and found that the average DI was 25.2 ± 2.4 mm²/mmHg when inflating the EndoFLIP balloon to 40 mL, with no significant variations when measured at 10, 20, and 30 mL consecutively. This study also evaluated a subgroup of patients with gastroparesis of various etiologies (diabetic, idiopathic, and post-fundoplication) and found that the pyloric DI decreased significantly at all evaluated volumes, establishing a normality threshold value greater than 10 mm²/mmHg.

Zhen and colleagues evaluated another larger cohort of healthy volunteers and found D values of 13.0 ± 2.5, 14.3 ± 1.8, and 17.2 ± 2.0 mm, DI values of 10.9 ± 4.8, 11.3 ± 5.8, and 11.1 ± 4.3 mm²/mmHg, and P values of 12.5 ± 3.9, 15.8 ± 4.8, and 21.7 ± 5.3 mmHg for distensions of 40, 50, and 60 mL, respectively[22].

Various series have evaluated these measurements in patients with gastroparesis. Jacques and colleagues[23] and Malik and colleagues[24] evaluated patients with diabetic gastroparesis (DG) and idiopathic gastroparesis (IG) and found DI values at 40 mL inflation of 11.7 and 10.0 ± 1.3 mm²/mmHg, respectively. Although the results obtained in these studies did not define a definitive cutoff point for DI with a high discriminative capacity between healthy and sick subjects, it appears that values below 10 mm²/mmHg could identify most patients with gastroparesis. The population with values between 10 and 25.2 ± 2.4 mm²/mmHg

should be characterized in prospective studies, as those with values close to the lower limit could correspond to false negatives.

Desprez and colleagues compared pyloric DI among three groups: healthy volunteers, patients with DGP, and patients with IG. They also examined the clinical characteristics of the diabetic patients in detail. For this study, DI values greater than 10 mm²/mmHg were considered normal. The results showed that the DI measured with 40 mL inflation was lower in the DGP and IG groups, specifically 10.8 ± 0.9 mm²/mmHg and 14.8 ± 2.2 mm²/mmHg, respectively, compared to the healthy volunteer group, which had a DI of 25.2 ± 2.3 mm²/mmHg ($p < 0.005$). A reduced pyloric DI was observed in 56.5% of the DGP patients, 51.5% of the IG patients, and 10% of the healthy volunteers. No correlation was found between the pyloric sphincter measurements and diabetes-related characteristics, including blood glucose levels, glycated hemoglobin, type of diabetes *mellitus*, neuropathy, or the use of glucagon-like peptide-1 (GLP-1) agonists. Both DI and P of the pyloric sphincter were altered in DGP and IG, while distensibility did not correlate with diabetes parameters[25]. **Table 2** summarizes the different variables measured in these studies.

Based on these findings, subsequent research has focused on determining whether DI measurement could predict the clinical outcomes of therapies specifically targeting the pylorus, such as HBPD, BT, or G-POEM. For HBPD, it has been shown that patients who experience greater symptomatic relief had lower DI values before dilation (7.2 ± 1.0 mm²/mmHg)[26]. The EsoFLIP (dilation balloon with incorporated EndoFLIP) could be a useful strategy to improve the success rate of this procedure, as it safely allows surpassing the dilation target threshold of 18-20 mm; in selected cases, it achieves residual diameters of up to 30 mm without increasing the complication rate[27].

Regarding the use of BT, DI values less than 8-10 mm²/mmHg predict a good symptomatic response post-intervention[28]. Saadi and colleagues also demonstrated the utility of EndoFLIP in predicting symptom response. Besides conventional measurements, they evaluated elasticity (very similar to DI, see the Operational Characteristics section). Patients with greater pre-BT elasticity showed marked improvement in nausea ($r = -0.34$, $p = 0.03$) and early satiety ($r = -0.34$, $p = 0.04$) at eight weeks. Interestingly, patients with higher preoperative DI experienced less abdominal pain eight weeks postoperatively, while those with lower DI, CSA, and D had more severe symptoms of nausea and vomiting[18].

Recent studies have focused on evaluating the role of EndoFLIP in the treatment of patients who are candidates for G-POEM. Preoperative data from Jacques and colleagues[23] showed that DI values below 9.2 mm²/mmHg predict clinical success at three months. Postoperatively, Vosoughi and colleagues demonstrated that CSA measurement appears to be the best predictor of clinical success and increased gastric emptying, with values greater than 154 mm² at a distension volume of 40 mL predicting clinical success at one year with a sensitivity and specificity of 71% and 91%, respectively[20]. Additionally, increases greater than 20% in CSA compared to the preoperative value correlate with clinical success[30]. This suggests that EndoFLIP could be used both before and after the proce-

Table 2. Pyloric EndoFLIP Measurements in Healthy and Gastroparesis Patients

Study	Etiology of Gastroparesis	Inflation Volume (mL)	Average Pyloric Diameter (mm)	Distensibility Index (mm²/mm Hg)	Average Pressure (mmHg)	CSA (mm²)
Gourcerol, et al.	Healthy patients	40	-	25.2	-	-
Zheng, et al.	Healthy patients	40	13.0 ± 2.5	10.9 ± 3.8	12.5 ± 3.9	138.6 ± 55.4
		50	14.3 ± 1.8	11.3 ± 5.8	15.8 ± 4.8	162.4 ± 39.2
Jacques, et al.	50% diabetic, 20% idiopathic, 25% miscellaneous*, 5% post-surgical	40	13.9	11.7	11.7	152.2
		50	17.3	8.1	28.9	234.5
Malik, et al.	72% idiopathic, 28% diabetic	40	12.2 ± 0.44	10.0 ± 1.3	18 ± 1.23	125.2 ± 9.15
		50	14.1 ± 0.41	6.0 ± 1.3	32.5 ± 1.55	164.7 ± 10.2

*15% secondary to Sjögren's syndrome, 5% to Parkinson's disease, and 5% to systemic sclerosis. Author's own research.

dure to help predict or confirm the efficacy of pyloromyotomy, guiding the procedure similarly to its use for the LES in patients with achalasia.

In Colombia, the limited number of specialized centers in gastrointestinal physiology and the high cost of EndoFLIP technology compared to other diagnostic strategies restrict its reproducibility and negatively impact the characterization and appropriate selection of pylorus-targeted therapies. Overcoming these obstacles could lead to its routine use and inclusion in local guidelines for managing patients with refractory gastroparesis.

CONCLUSION

Pyloric EndoFLIP is an attractive complementary diagnostic tool for the characterization of gastroparesis, especially in cases of refractory gastroparesis, to initial traditional management. Most studies have shown an inverse correlation between pyloric distensibility, gastric emptying, and gastroparesis symptoms. This could allow for the indivi-

dualization of each case by identifying the characteristics of the pylorus, guiding towards a better management strategy, and, in many cases, predicting clinical response.

Ethical Considerations

This study does not disclose any information that could identify patients, so it did not require informed consent or protocol approval by an institutional ethics committee in accordance with the Declaration of Helsinki and Resolution 008430 of October 4, 1993.

Funding Sources

No sponsorship was received from any of the participating institutions for the preparation of this article.

Conflict of Interests

The authors declare no conflict of interest.

REFERENCES

1. Lacy BE, Wise JL, Cangemi DJ. Gastroparesis: time for a paradigm change. Curr Opin Gastroenterol. 2023;39(6):503-511. https://doi.org/10.1097/MOG.0000000000000978
2. Wadhwa V, Mehta D, Jobanputra Y, Lopez R, Thota PN, Sanaka MR. Healthcare utilization and costs associated with gastroparesis. World J Gastroenterol. 2017;23(24):4428-4436. https://doi.org/10.3748/wjg.v23.i24.4428
3. Ye Y, Yin Y, Huh SY, Almansa C, Bennett D, Camilleri M, et al. Epidemiology, Etiology, and Treatment of Gastroparesis: Real-World Evidence From a Large US National Claims Database. Gastroenterology. 2022;162(1):109-121.e5. https://doi.org/10.1053/j.gastro.2021.09.064
4. Camilleri M, Sanders KM. Gastroparesis. Gastroenterology. 2022 ;162(1):68-87.e1. https://doi.org/10.1053/j.gastro.2021.10.028
5. Mayor V, Aponte D, Prieto R, Orjuela E. Diagnóstico y tratamiento actual de la gastroparesia: una revisión sistemática de la literatura. Rev. colomb. Gastroenterol. 2020;35(4):471-484. https://doi.org/10.22516/25007440.561
6. Grover M, Farrugia G, Stanghellini V. Gastroparesis: a turning point in understanding and treatment. Gut. 2019;68(12):2238-2250. https://doi.org/10.1136/gutjnl-2019-318712
7. Olausson EA, Störsrud S, Grundin H, Isaksson M, Attvall S, Simrén M. A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastro-

paresis: a randomized controlled trial. Am J Gastroenterol. 2014;109(3):375-385. https://doi.org/10.1038/ajg.2013.453
8. Soliman H, Gourcerol G. Targeting the pylorus in gastroparesis: From physiology to endoscopic pyloromyotomy. Neurogastroenterol Motil. 2023;35(2):e14529. https://doi.org/10.1111/nmo.14529
9. Lacy BE, Tack J, Gyawali CP. AGA Clinical Practice Update on Management of Medically Refractory Gastroparesis: Expert Review. Clin Gastroenterol Hepatol. 2022;20(3):491-500. https://doi.org/10.1016/j.cgh.2021.10.038
10. Bromer MQ, Friedenberg F, Miller LS. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest Endosc. 2005;61(7):833-839. https://doi.org/10.1016/S0016-5107(05)00328-7
11. Shada AL, Dunst CM, Pescarus R, Speer EA, Cassera M, Reavis KM, et al. Laparoscopic pyloroplasty is a safe and effective first-line surgical therapy for refractory gastroparesis. Surg Endosc. 2016;30(4):1326-1332. https://doi.org/10.1007/s00464-015-4385-5
12. Shen S, Luo H, Vachaparambil C. Gastric peroral endoscopic pyloromyotomy versus gastric electrical stimulation in the treatment of refractory gastroparesis: a propensity score-matched analysis of long-term outcomes. Endoscopy. 2020;52(5):349-358. https://doi.org/10.1055/a-1111-8566
13. Spadaccini M, Maselli R, Chandrasekar VT, Anderloni A, Carrara S, Galtieri PA, et al. Gastric peroral endoscopic

pyloromyotomy for refractory gastroparesis: a systematic review of early outcomes with pooled analysis. Gastrointest Endosc. 2020;91(4):746-752. https://doi.org/10.1016/j.gie.2019.11.039

14. Mohan BP, Chandan S, Jha LK, Khan SR, Kotagiri R, Kassab LL, et al. Clinical efficacy of gastric per-oral endoscopic myotomy (G-POEM) in the treatment of refractory gastroparesis and predictors of outcomes: a systematic review and meta-analysis using surgical pyloroplasty as a comparator group. Surg Endosc. 2020;34(8):3352-3367. https://doi.org/10.1007/s00464-019-07135-9

15. Vohra I, Gopakumar H, Adler DG. G-POEM for gastroparesis: past, present and future. Curr Opin Gastroenterol. 2023;39(5):390-396. https://doi.org/10.1097/MOG.0000000000000950

16. Hani A, Delgado D, Bejarano J, Meza D, Ramírez R, Pinto M, et al. EndoFLIP: una nueva tecnología. Rev. colomb. Gastroenterol. 2021;36(2):227-240. https://doi.org/10.22516/25007440.741

17. Lorenz F, Brunner S, Berlth F, Dratsch T, Babic B, Fuchs HF, et al. Using an Endoluminal Functional Lumen Imaging Probe (EndoFLIP™) to Compare Pyloric Function in Patients with Gastroparesis to Patients After Esophagectomy. J Gastrointest Surg. 2023;27(4):682-690. https://doi.org/10.1007/s11605-022-05502-x

18. Saadi M, Yu D, Malik Z, Parkman HP, Schey R. Pyloric sphincter characteristics using EndoFLIP® in gastroparesis. Rev Gastroenterol Mex (Engl Ed). 2018;83(4):375-384. English, Spanish. https://doi.org/10.1016/j.rgmx.2018.02.013

19. Yim B, Gregor L, Siwiec RM, Al-Haddad M, Nowak TV, Wo JM. Pyloric Functional Lumen Imaging Probe Measurements Are Dependent on Balloon Position. J Neurogastroenterol Motil. 2023;29(2):192-99. https://doi.org/10.5056/jnm22053

20. Desprez C, Jacques J, Clavier T, Wallenhorst T, Leroi AM, Gourcerol G. Impact of anesthetics on pyloric characteristics measured using the EndoFLIP® system in patients with gastroparesis. Neurogastroenterol Motil. 2023;35(10):e14651. https://doi.org/10.1111/nmo.14651

21. Gourcerol G, Tissier F, Melchior C, Touchais JY, Huet E, Prevost G, et al. Impaired fasting pyloric compliance in gastroparesis and the therapeutic response to pyloric dilatation. Aliment Pharmacol Ther. 2015;41(4):360-367. https://doi.org/10.1111/apt.13053

22. Zheng T, Vosoughi K, Busciglio I, Tebay L, Burton D, Camilleri M. Fasting pyloric diameter and distensibility by functional endoluminal imaging probe in unsedated healthy volunteers. Neurogastroenterol Motil. 2022;34(10):e14386. https://doi.org/10.1111/nmo.14386

23. Jacques J, Pagnon L, Hure F, Legros R, Crepin S, Fauchais AL, et al. Peroral endoscopic pyloromyotomy is efficacious and safe for refractory gastroparesis: prospective trial with assessment of pyloric function. Endoscopy. 2019;51(1):40-49. https://doi.org/10.1055/a-0628-6639

24. Malik Z, Sankineni A, Parkman HP. Assessing pyloric sphincter pathophysiology using EndoFLIP in patients with gastroparesis. Neurogastroenterol Motil. 2015;27(4):524-31. https://doi.org/10.1111/nmo.12522

25. Desprez C, Chambaz M, Melchior C, Basile P, Prevost G, Jacques J, et al. Assessment of pyloric sphincter distensibility and pressure in patients with diabetic gastroparesis. Neurogastroenterol Motil. 2021;33(8):e14064. https://doi.org/10.1111/nmo.14064

26. Jehangir A, Malik Z, Petrov RV, Parkman HP. EndoFLIP and pyloric dilation for gastroparesis symptoms refractory to pyloromyotomy/pyloroplasty. Dig Dis Sci. 2020;66(8):2682-2690. https://doi.org/10.1007/s10620-020-06510-0

27. Murray FR, Schindler V, Hente JM, Fischbach LM, Schnurre L, Deibel A, et al. Pyloric dilation with the esophageal functional lumen imaging probe in gastroparesis improves gastric emptying, pyloric distensibility, and symptoms. Gastrointest Endosc. 2021;94(3):486-494. https://doi.org/10.1016/j.gie.2021.03.022

28. Desprez C, Roman S, Leroi AM, Gourcerol G. The use of impedance planimetry (Endoscopic Functional Lumen Imaging Probe, EndoFLIP®) in the gastrointestinal tract: A systematic review. Neurogastroenterol Motil. 2020;32(9):e13980. https://doi.org/10.1111/nmo.13980

29. Vosoughi K, Ichkhanian Y, Jacques J, Aadam AA, Benias PC, Law R, et al. Role of endoscopic functional luminal imaging probe in predicting the outcome of gastric peroral endoscopic pyloromyotomy (with video). Gastrointest Endosc. 2020;91(6):1289-1299. https://doi.org/10.1016/j.gie.2020.01.044

30. Conchillo JM, Straathof JWA, Mujagic Z, Brouns JH, Bouvy ND, Keszthelyi D, et al. Gastric peroral endoscopic pyloromyotomy for decompensated gastroparesis: comprehensive motility analysis in relation to treatment outcomes. Endosc Int Open. 2021;9(2):E137-E144. https://doi.org/10.1055/a-1311-0859